Share this doc
Open By Default

A-2022-000371

Health CanadaReleased September 2022 • 4 pages
Request: The Health Canada approval letter for Vertex Pharmaceutical's trial to be carried out in Canada: A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (ClinicalTrials.gov Identifier: NCT04786262).
Report an issue with this document »

Want to support this project? Subscribe to the IJF today!

CreditsFounder: Matt Malone • Data acquisition and processing: Adam Soames, Ashley Desautels • Development: Daniel Nass, Sam Park, Martin Allen • Document hosting: DocumentCloud • Additional contributors
Get Involved
Contact us to contribute your documents, suggest an ATIP request or support the project.
Open By DefaultHomeMy documentsMethodologyFrequently asked questions